title: [The study of hypotensive action of dinitrosyl-iron complex  with glutathione containing drug oxacom in healthy  volunteers].
abstract: On the basis of earlier executed studies of hypotensive effect of dinitrosyl iron complexes (DNIC) with glutathione, the drug has been created in industrial conditions named oxacom. Preliminary pharmacological studies of oxacom have not revealed negative qualities. The drug has been now tested in 14 healthy men in whom at single intravenous introduction it caused typical response - a decrease of diastolic as well as systolic arterial pressure on 24-27 mmHg through 3-4 min with subsequent very slow restoration in 8-10 hours. The heart rate after initial rise was quickly normalized. Echocardiography revealed unaltered cardiac output in spite of reduced cardiac filling by 28%. The multilateral analysis of clinical and biochemical data has revealed an absence of essential alterations which could lead to pathological consequences. The drug is recommended for carrying out of the second phase of clinical trial. The comparative study of the efficiency of hypotensive action of oxacom, S-nitrosoglutathione (GS-NO) and sodium nitrite (NO2) in rats has shown that the duration of effect was the greatest at oxacom action.
authors: E I
authors: EI
authors: Chazov
authors: O V
authors: OV
authors: Rodnenkov
authors: A V
authors: AV
authors: Zorin
authors: V L
authors: VL
authors: Lakomkin
authors: V V
authors: VV
authors: Gramovich
authors: O N
authors: ON
authors: Vyborov
authors: A G
authors: AG
authors: Dragnev
authors: A A
authors: AA
authors: Timoshin
authors: L I
authors: LI
authors: Buriachkovskaia
authors: A A
authors: AA
authors: Abramov
authors: A B
authors: AB
authors: Dobrovol'skiĭ
authors: G V
authors: GV
authors: Maksimov
authors: V P
authors: VP
authors: Masenko
authors: E V
authors: EV
authors: Arzamastsev
authors: V I
authors: VI
authors: Kapel'ko
authors: A F
authors: AF
authors: Vanin
mesh_terms: D000328:Adult; D000818:Animals; D001682:Biological Availability; D001794:Blood Pressure / Q000187:drug effects*; D004353:Drug Evaluation, Preclinical / Q000379:methods; D016903:Drug Monitoring / Q000379:methods; D005978:Glutathione / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D007022:Hypotension / Q000139:chemically induced; D007262:Infusions, Intravenous; D007501:Iron / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D008297:Male; D009569:Nitric Oxide / Q000378:metabolism; D009589:Nitrogen Oxides / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D026422:S-Nitrosoglutathione / Q000493:pharmacokinetics*; D012977:Sodium Nitrite / Q000493:pharmacokinetics*; D013810:Therapeutic Equivalency; D035703:Therapies, Investigational; D016896:Treatment Outcome
chemical_list: D009589:Nitrogen Oxides; D009569:Nitric Oxide; D026422:S-Nitrosoglutathione; C073661:dinitrosyl iron complex; D007501:Iron; D005978:Glutathione; D012977:Sodium Nitrite